California State Teachers Retirement System trimmed its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 3.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 344,498 shares of the medical equipment provider’s stock after selling 10,906 shares during the period. California State Teachers Retirement System’s holdings in Zimmer Biomet were worth $37,564,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of the company. Bedel Financial Consulting Inc. bought a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $111,000. Massey Quick Simon & CO. LLC lifted its stake in shares of Zimmer Biomet by 100.0% during the 1st quarter. Massey Quick Simon & CO. LLC now owns 1,200 shares of the medical equipment provider’s stock worth $131,000 after acquiring an additional 600 shares during the last quarter. We Are One Seven LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $137,000. Adviser Investments LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $144,000. Finally, BKS Advisors LLC bought a new stake in shares of Zimmer Biomet during the 1st quarter worth approximately $208,000. 87.39% of the stock is owned by institutional investors and hedge funds.
In other news, VP Tony W. Collins sold 1,330 shares of Zimmer Biomet stock in a transaction on Monday, April 30th. The stock was sold at an average price of $116.73, for a total value of $155,250.90. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Katarzyna Mazur-Hofsaess sold 8,765 shares of Zimmer Biomet stock in a transaction on Tuesday, May 22nd. The shares were sold at an average price of $113.61, for a total value of $995,791.65. Following the completion of the transaction, the insider now owns 25,447 shares in the company, valued at $2,891,033.67. The disclosure for this sale can be found here. Company insiders own 0.71% of the company’s stock.
Zimmer Biomet opened at $113.38 on Friday, according to Marketbeat.com. The firm has a market cap of $23.35 billion, a price-to-earnings ratio of 14.12, a PEG ratio of 2.24 and a beta of 1.14. Zimmer Biomet Holdings Inc has a 52 week low of $104.28 and a 52 week high of $133.49. The company has a current ratio of 1.69, a quick ratio of 1.07 and a debt-to-equity ratio of 0.79.
Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, April 26th. The medical equipment provider reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.89 by $0.02. Zimmer Biomet had a return on equity of 14.36% and a net margin of 21.81%. The business had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same period last year, the business posted $2.13 EPS. The business’s revenue was up 2.1% compared to the same quarter last year. equities research analysts forecast that Zimmer Biomet Holdings Inc will post 7.67 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 31st. Stockholders of record on Friday, June 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet’s dividend payout ratio is presently 11.96%.
Zimmer Biomet Profile
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.